Activator of G Protein Signaling 3 Modulates Prostate Tumor Development and Progression

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2019 Jun 20

PMID 31215992

Citations 7

Authors

Timothy O Adekoya

Nikia Smith

Temilade Aladeniyi

Joe B Blumer

Xiaoxin L Chen

Ricardo M Richardson

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is a leading cause of cancer death among men, with greater prevalence of the disease among the African American population in the USA. Activator of G-protein signaling 3 (AGS3/G-protein signaling modulator 1) was shown to be overexpressed in prostate adenocarcinoma relative to the prostate gland. In this study, we investigated the correlation between AGS3 overexpression and PCa malignancy. Immunoblotting analysis and real-time quantitative-PCR showed increase in AGS3 expression in the metastatic cell lines LNCaP (~3-fold), MDA PCa 2b (~2-fold), DU 145 (~2-fold) and TRAMP-C1 (~20-fold) but not in PC3 (~1-fold), relative to control RWPE-1. Overexpression of AGS3 in PC3, LNCaP and MDA PCa 2b enhanced tumor growth. AGS3 contains seven tetratricopeptide repeats (TPR) and four G-protein regulatory (GPR) motifs. Overexpression of the TPR or the GPR motifs in PC3 cells had no effect in tumor growth. Depletion of AGS3 in the TRAMP-C1 cells (TRAMP-C1-AGS3-/-) decreased cell proliferation and delayed wound healing and tumor growth in both C57BL/6 (~3-fold) and nude mice xenografts, relative to control TRAMP-C1 cells. TRAMP-C1-AGS3-/- tumors also exhibited a marked increase (~5-fold) in both extracellular signal-regulated kinase (ERK) 1/2 and P38 mitogen-activated protein kinase (MAPK) activation, which correlated with a significant increase (~3-fold) in androgen receptor (AR) expression, relative to TRAMP-C1 xenografts. Interestingly, overexpression of AGS3 in TRAMP-C1-AGS3-/- cells inhibited ERK activation and AR overexpression as compared with control TRAMP-C1 cells. Taken together, the data indicate that the effect of AGS3 in prostate cancer development and progression is probably mediated via a MAPK/AR-dependent pathway.

Citing Articles

CXCR1 Expression in MDA-PCa-2b Cell Upregulates ITM2A to Inhibit Tumor Growth.

Adekoya T, Smith N, Kothari P, Dacanay M, Li Y, Richardson R Cancers (Basel). 2025; 16(24.

PMID: 39766038 PMC: 11674668. DOI: 10.3390/cancers16244138.

Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.

Mao G, Yang D, Liu B, Zhang Y, Ma S, Dai S Respir Res. 2023; 24(1):176.

PMID: 37415224 PMC: 10324233. DOI: 10.1186/s12931-023-02402-9.

Identifying GPSM Family Members as Potential Biomarkers in Breast Cancer: A Comprehensive Bioinformatics Analysis.

Dang H, Ta H, Nguyen T, Anuraga G, Wang C, Lee K Biomedicines. 2021; 9(9).

PMID: 34572330 PMC: 8471503. DOI: 10.3390/biomedicines9091144.

Knockdown of GPSM1 Inhibits the Proliferation and Promotes the Apoptosis of B-Cell Acute Lymphoblastic Leukemia Cells by Suppressing the ADCY6-RAPGEF3-JNK Signaling Pathway.

Zhang Y, Zhou B, Sun J, He Q, Zhao Y Pathol Oncol Res. 2021; 27:643376.

PMID: 34257610 PMC: 8262160. DOI: 10.3389/pore.2021.643376.

Host versus cell-dependent effects of β-arrestin 1 expression in prostate tumorigenesis.

Adekoya T, Smith N, Thomas A, Lane T, Burnette N, Rivers E Carcinogenesis. 2021; 42(5):772-783.

PMID: 33710266 PMC: 8163054. DOI: 10.1093/carcin/bgab021.

References

Murillo-Garzon V, Gorrono-Etxebarria I, Akerfelt M, Puustinen M, Sistonen L, Nees M . Frizzled-8 integrates Wnt-11 and transforming growth factor-β signaling in prostate cancer. Nat Commun. 2018; 9(1):1747. PMC: 5931552. DOI: 10.1038/s41467-018-04042-w. View

Choi I, Ahn D, Choi J, Cha H, Ock M, You E . Regulation of Airway Inflammation by G-protein Regulatory Motif Peptides of AGS3 protein. Sci Rep. 2016; 6:27054. PMC: 4895231. DOI: 10.1038/srep27054. View

Singh S, Singh U, Grizzle W, Lillard Jr J . CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004; 84(12):1666-76. DOI: 10.1038/labinvest.3700181. View

Branham-OConnor M, Robichaux 3rd W, Zhang X, Cho H, Kehrl J, Lanier S . Defective chemokine signal integration in leukocytes lacking activator of G protein signaling 3 (AGS3). J Biol Chem. 2014; 289(15):10738-10747. PMC: 4036190. DOI: 10.1074/jbc.M113.515031. View

Foster B, Gingrich J, Kwon E, Madias C, Greenberg N . Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997; 57(16):3325-30. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Xie Q, Liu Y, Cai T, Horton C, Stefanson J, Wang Z . Dissecting cell-type-specific roles of androgen receptor in prostate homeostasis and regeneration through lineage tracing. Nat Commun. 2017; 8:14284. PMC: 5264212. DOI: 10.1038/ncomms14284. View

Karantanos T, Corn P, Thompson T . Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 2013; 32(49):5501-11. PMC: 3908870. DOI: 10.1038/onc.2013.206. View

Groves B, Gong Q, Xu Z, Huntsman C, Nguyen C, Li D . A specific role of AGS3 in the surface expression of plasma membrane proteins. Proc Natl Acad Sci U S A. 2007; 104(46):18103-8. PMC: 2084303. DOI: 10.1073/pnas.0709282104. View

10.

Pizzinat N, Takesono A, Lanier S . Identification of a truncated form of the G-protein regulator AGS3 in heart that lacks the tetratricopeptide repeat domains. J Biol Chem. 2001; 276(20):16601-10. DOI: 10.1074/jbc.M007573200. View

11.

Oner S, Vural A, Lanier S . Translocation of activator of G-protein signaling 3 to the Golgi apparatus in response to receptor activation and its effect on the trans-Golgi network. J Biol Chem. 2013; 288(33):24091-103. PMC: 3745352. DOI: 10.1074/jbc.M112.444505. View

12.

Cao X, Qin J, Xie Y, Khan O, Dowd F, Scofield M . Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene. 2006; 25(26):3719-34. DOI: 10.1038/sj.onc.1209408. View

13.

Sanada K, Tsai L . G protein betagamma subunits and AGS3 control spindle orientation and asymmetric cell fate of cerebral cortical progenitors. Cell. 2005; 122(1):119-31. DOI: 10.1016/j.cell.2005.05.009. View

14.

Bowers M, Hopf F, Chou J, Guillory A, Chang S, Janak P . Nucleus accumbens AGS3 expression drives ethanol seeking through G betagamma. Proc Natl Acad Sci U S A. 2008; 105(34):12533-8. PMC: 2527946. DOI: 10.1073/pnas.0706999105. View

15.

Nadella R, Blumer J, Jia G, Kwon M, Akbulut T, Qian F . Activator of G protein signaling 3 promotes epithelial cell proliferation in PKD. J Am Soc Nephrol. 2010; 21(8):1275-80. PMC: 2938587. DOI: 10.1681/ASN.2009121224. View

16.

Waugh D, Wilson C . The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14(21):6735-41. DOI: 10.1158/1078-0432.CCR-07-4843. View

17.

Vural A, Al-Khodor S, Cheung G, Chong-Shan Shi , Srinivasan L, McQuiston T . Activator of G-Protein Signaling 3-Induced Lysosomal Biogenesis Limits Macrophage Intracellular Bacterial Infection. J Immunol. 2015; 196(2):846-56. PMC: 4811337. DOI: 10.4049/jimmunol.1501595. View

18.

Yowell C, Daaka Y . G protein-coupled receptors provide survival signals in prostate cancer. Clin Prostate Cancer. 2004; 1(3):177-81. DOI: 10.3816/cgc.2002.n.020. View

19.

Feldman B, Feldman D . The development of androgen-independent prostate cancer. Nat Rev Cancer. 2002; 1(1):34-45. DOI: 10.1038/35094009. View

20.

Sato M, Gettys T, Lanier S . AGS3 and signal integration by Galpha(s)- and Galpha(i)-coupled receptors: AGS3 blocks the sensitization of adenylyl cyclase following prolonged stimulation of a Galpha(i)-coupled receptor by influencing processing of Galpha(i). J Biol Chem. 2004; 279(14):13375-82. DOI: 10.1074/jbc.M312660200. View